首页> 外文期刊>International Journal of Mosquito Research >Chloroquine drug response and resistance in patients with malaria in Khyber Pakhtunkhwa, Pakistan
【24h】

Chloroquine drug response and resistance in patients with malaria in Khyber Pakhtunkhwa, Pakistan

机译:巴基斯坦开伯尔·普赫图赫瓦省疟疾患者的氯喹药物反应和耐药

获取原文
           

摘要

Malaria is caused by infection with protozoan parasites belonging to the genus Plasmodium transmitted by female Anopheles species mosquitoes. The current study was designed to find resistance and response of chloroquine drug to malaria patients in Thall scout hospital, Khyber pakhtunkhwa, Pakistan from January 2011 to march 2015. The age of adult male patients having positive vivax malaria was 18 to 40 years. Both thick and thin slides were used for the diagnosis and species determination of malaria. The total number of patients included in the study were 518. Out of the 518 patients, 374 (72.2%) were treated with chloroquine and the remaining 144 (27.8%) were given arthemether/lumafantrine combination. 374 patients having positive malaria symptoms was treated with chloroquine, 171 (45.72%) were asymptomatic after 24 hours, 98 (26.2%) after 48 hours, 78 (20.86%) after 72 hours, while 27(7.22%) were found to be resistant to chloroquine. Out of the 144 patients having positive malaria treated with artemether/lumafantrine 62 (43.06%) were asymptomatic after 24 hours, 65(45.14%) after 48 hours, 13 (9.03%) after 72 hours while 4 (2.78%) had still positive symptoms of malaria.
机译:疟疾是由雌性按蚊属蚊子传播的原生动物寄生虫感染引起的。本研究旨在发现2011年1月至2015年3月在巴基斯坦开伯尔-普赫图赫瓦省Thall scout医院的氯喹药物对疟疾患者的耐药性和反应。间日疟原虫呈阳性的成年男性患者年龄为18至40岁。厚玻片和薄玻片均用于疟疾的诊断和种类确定。纳入研究的患者总数为518名。在518名患者中,有374名(72.2%)接受了氯喹治疗,其余144名(27.8%)接受了蒿甲醚/ lumantantine组合治疗。 374例疟疾阳性患者接受氯喹治疗,24小时后无症状171例(45.72%),48小时后无症状98例(26.2%),72小时后78例(20.86%)无症状,27例(7.22%)被发现耐氯喹。在144例接受蒿甲醚/拉马替林治疗的疟疾呈阳性的患者中,有62例(43.06%)在24小时后无症状,在48个小时后有65(45.14%),在72个小时后无症状(13.(9.03%)),而4例(2.78%)仍呈阳性疟疾的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号